

PQRI Manufacturing Technical Committee
July 10, 2008
Meeting Minutes

The MTC had a meeting on July 10, 2008 at Pfizer's Peapack, NJ facility.

Antitrust Statement

MTC Chair started the meeting by reading the following antitrust statement: "Our discussions today are subject to the anti-trust guidance applicable in the U.S. Nothing discussed at this meeting is intended to restrict the individual decision-making of any member company or to represent an agreement to coordinate marketing or sales conduct. Those participating in this meeting are instructed to avoid discussion of competitively sensitive subjects, including, confidential marketing, sales, and pricing information."

Specification Design & Lifecycle Management Work Plan

The latest version of the white paper has been commented on by the WG. Unfortunately, GSK is undergoing some reorganizations and the Chair of the WG, will be busy with this for the next few months. Liaison is working on getting someone else from the WG to work on the revisions to the document. The MTC will hopefully get to see the WG's final version for comment by the end of the summer. It was suggested that the latest version be circulated to the MTC for their review **ONLY** (not to be forwarded to others). Liaison will discuss this with the WG.

Action Item: Liaison will discuss sharing the latest version of the document with the MTC prior to revisions being completed.

Biologicals Inspection Survey Work Group

Liaison mentioned that no conferences have been scheduled for presentations. He mentioned that he tried to contact a person of CBER to discuss, but she never got back in touch with him.

FDA rep mentioned that there is a FDA GMP conference in the fall (October) and maybe this would be a possibility. He forwarded information to the MTC during the call on this conference. However, the agenda for this meeting has already been set.

It was agreed that the work of this WG has been completed and will not be discussed at future MTC meetings. If requests for presentations do come in they will be looked at.

Steering Committee Update

The last SC minutes for the May 7th meeting were discussed. Chair mentioned that there is now a Vice Chair for the MTC. He mentioned that he was not resigning as mentioned in the minutes.

He also mentioned that the SC is looking for a Vice Chair for the SC, since the Chair's term ends in September and Vice Chair will step up to Chair. The SC is also looking for a new chair for the BTC, since its Chair is resigning at the end of the year.

The group then reviewed the various presentations and proposals made to the SC by NIPTE. The first one discussed was the general overview of what NIPTE is and their goals. A question was raised as to whether the courses they are planning are for students (graduate or undergraduate?) or for use by pharmaceutical companies for their employees. PQRI Executive Secretary said she would ask them at the NIPTE/PQRI meeting the week of the 14th.

Action Item: PQRI Ex. Secretary to ask NIPTE who the courses they are developing are targeted for.

The group then discussed the NIPTE Excipient Proposal. There was some concern as to whether this was just development of ASTM standard tests or if these would then lead to additional compendial specifications. FDA Rep mentioned that ASTM is for standard test methodologies and not chemical specifications. The MTC's concern was what the various compendial organizations might do with these "fit for use" tests. It was also mentioned that these types of testing and specifications will not be universally necessary for every excipients for every product. The requirements will be dependent on the product, formulation and process used. However, the MTC felt that the science proposed here is good and the project should be supported. The feeling was that data generated would be useful in helping companies to determine what they should evaluate as part of their QbD evaluations during development. It was pointed out that QbD was not mentioned in the proposal and should be. There may be some issues since the proposal is to only look at binary mixtures and it is known that most issues are not due to binary interactions, but are much more complex. It was agreed that if this work does proceed the MTC needs to be involved, not just the DTC, since usually processing issues with excipients show up later during manufacturing, rather than during development.

A few questions on the proposal were also how the IPEC/PQRI survey on excipients could be utilized for this work. It was also mentioned that the reliance on surveying industry for examples is always problematic since most companies are willing to share issues. This will be a challenge for this work.

MTC member has agreed to represent the MTC at the meeting of NITPE and PQRI on July 15th since Chair is unavailable that day. CHPA rep may also participate.

The Stability Shelf Life update was then discussed also. FDA rep mentioned he had concerns with the pooling of data and statistics being used for this work. He mentioned that the statistics need to be looked at very carefully when proposing a shelf life.

The PODP work plan proposal was then reviewed.

The SC would like to try and capture more publicity with the work being done by the various work groups. Examples of news bulletins were shared with the SC and TC chairs. Chair asked the MTC liaisons with the WG's to keep this in mind.

Action Item: Chair to share the sample news bulletins with the MTC. (the email with samples is attached to the meeting minutes email).

Chair also shared an analysis done by DTC rep on overlap of projects looking at QbD. This was for information purposes only.

Risk Management Work Group

Chair had forwarded the Risk Management white paper to the MTC prior to the meeting for organization review. The MTC agreed to get comments from their respective organizations back to WG chair by August 10th (one month for review). CHPA Rep mentioned that there was an ICH Q10 meeting in November and it would be good to get this document out prior to that meeting (hopefully in October). Member had mentioned that the WG had thought publication of the document in either Pharmaceutical Engineering or Pharmaceutical Technology would be good. The MTC agreed that we should approach Pharm Tech to publish this, especially since ISPE is no longer a PQRI member and the bad experience we had in having them publish the Process Robustness paper. The MTC discussed how to publish the document, case studies and training guides, since this is a large document. It was agreed that we should ask Pharm Tech if we could do it as a series. MTC Chair will discuss with WG Chair to get his thoughts on this.

Action Item: MTC Chair to discuss publication strategy with WG Chair. (**POST MEETING NOTE:** Discussion held with WG chair and it was agreed to try and publish as a series in Pharm Tech. MTC Chair will discuss with ECAS.)

The MTC also discussed the possibilities of holding conferences on this. It was mentioned that it would be nice to hold some short training conferences regionally. CHPA rep mentioned that it might be possible to have a presentation at the ICH Conference in the Fall.

Action Item: CHPA rep to look into the possibility of a presentation at the ICH conference.

Work Group Ideas

The OOS work plan will be updated by PDA rep to include the comments made by FDA. Bruce stated that the SC did not reject the work plan, it did not accept it at the time it was mentioned because no one from the MTC was there to present the plan. MTC Chair will present to the SC at the August meeting if the revision can be completed in time. PDA rep will also inform the group of the proposed chair for the work group.

Action Item: PDA rep to revise the OOS work plan as soon as possible

Action Item: MTC Chair to present the work plan to the SC at the August meeting.

Other potential work groups discussed included one on Design Space, how to apply Q8 with case studies, how and where to apply it.

Real time release was discussed. This would cover how to interpret documents and case studies for real time release. Chair mentioned there was a publication on what AstraZeneca and presentations on what Merck did for real time release.

Action Item: Chair to send the paper and presentations on real time release to the MTC. (The documents are attached to the email for the minutes.)

Other topics mentioned were control strategies with examples; criticality; application of Q9 and Q10; cross contamination prevention/isolation with high potency compounds and biologicals; comprehensive recommendation for product experiences including annual records review, evaluation of product returns, marketing information, etc. and then using this information to feed back into design (these are currently done separately, but there is no requirement, so hence it's not done, to tie these all together. It's part of Q10 and a Quality System.).

POST MEETING NOTE: A proposal for a project on Change Control for Pharmaceutical Manufacturing was discussed. There is a need for a detailed discussion/recommendation/model for an effective and compliant change control program that could be implemented in an operating production site. Such a project could crystallize and facilitate the preparation and use of individualized programs adapted to particular sites by the management of the sites.

The need exists for this because: Change in manufacturing introduces the concern for continued suitability/acceptability/utility of the products resulting from the changed conditions and practices as compared to the established/unchanged conditions and practices. Oversight (application review and inspection) is performed at intense levels because the assumption/conclusion is that change control is not well understood/accepted/recognized/implemented by the manufacturer.

If these concerns can be managed, facilitated by a successful MTC project product, important advances may be made in the quality of pharmaceuticals, including reduction in the intensity of the levels of oversight for manufacturing.

There are some treatments of change control already, this study/project would have to take note of them and build on them after some assessment as to their value.

Next Meeting

The next meeting is a teleconference on Thursday, August 14th. An agenda and call in information will be issued prior to the teleconference.

We also need a volunteer to host the October 9th face to face meeting.

Schedule of meetings:

2008

August 14 th	Teleconference
September 11 th	Teleconference
October 9 th	Face to Face (TBD)

November 13th
December 11th

Teleconference
Teleconference